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Abstract: HTLV-1-associated myelopathy/tropical spastic parapar-
esis (HAM/TSP) remains a challenging disease. Treatment options are
scarce, and their safety and efficacy are currently a matter of concern.
We present a case report describing our experience using cyclos-
porine in a patient with early HAM/TSP who started with a gait
disturbance at Vall d’Hebron University Hospital (Barcelona) from
August 2012 to October 2013. After 62 weeks of treatment, clinical
improvement was observed and proviral load diminished. No safety
concerns were observed.
Cyclosporine seems to be effective in new-onset HAM/TSP or in
chronic HAM/TSP that develops a relapse. However, the duration and
safety profile of this steroid-sparing therapy remain unknown and
should be further investigated.
(Medicine 94(1):e382)
Abbreviations: HAM/TSP = HTLV-1-associated myelopathy/
tropical spastic paraparesis, HTLV = human T-lymphotropic
virus, IPEC = Instituto de Pesquisa Clı́nica Evandro Chagas
disability score, SF-36 = SF-36 health survey scale, SPAST-88 =
spasticity scale-88 score, TLL = T-cell leukemia/lymphoma.
INTRODUCTION
H uman T-lymphotropic virus (HTLV) was the first retro-virus to be described.1 Currently, 4 types of HTLV have
been reported,2 with HTLV-1 being the most clinically relevant.
Approximately, 20 million people are infected with HTLV-1
and 5 million with HTLV-2 worldwide.3 HTLV-1 infection is
mainly present in the Sub-Saharan region, Japan, the Caribbean
region, and some parts of Latin America, whereas HTLV-2
infection predominates in specific ethnic groups in Africa and
America. Additionally, HTLV-2 infection has been found inD, Estrella Caballero, MD, and Israel Molina, MD
and 0.08% for HTLV-2. HTLV-1 was mainly diagnosed in the
migrant population.4
The HTLV-1 infection has been associated with 2 life-
threatening diseases, T-cell leukemia/lymphoma (TLL) and
HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP). Other manifestations, such as eye and skin invol-
vement, have also been related with HTLV-1.6,7
HAM/TSP is an inflammatory disease of the central
nervous system. The incidence of HAM/TSP was 5.3 cases
per 1000 HTLV-1-seropositive cases per year in a study carried
out in Brazil.8 Symptoms of the disease are insidious and
difficult to interpret at the onset of the disease. Paraparesis,
spasticity, urinary incontinence, lower back pain, and hyperre-
flexia are common but not specific findings, hindering both
diagnosis and follow-up. A new classification to make monitor-
ing of the therapeutic response easier was developed recently
using onset, progression, and activity criteria.9
Although HAM/TSP has been known for decades and its
consequences are devastating, treatment options are still scarce.
Initially, antiretroviral therapy was used with contradictory
results. Once the immune-mediated theory emerged, immuno-
suppressive therapy was studied. To date, cyclosporine and
interferon-a are the preferred immunosuppressive agents, even
though the evidence regarding their efficacy is limited.9,10
Host–virus interaction is crucial for the HTLV-1 spread
and the development of lymphocyte-mediated related diseases.
Immunomodulation with cyclosporine after HTLV-1 infection
in a rabbit model has shown a decrease of proviral load.11 In a
recent proof-of-concept study, 7 patients with HAM/TSP in an
early/progressive stage of the disease were treated with cyclos-
porine with encouraging results.10
Based on the cyclosporine proof-of-concept study, we
relate our experience with cyclosporine in a patient diagnosed
with an early HAM/TSP. We utilized the same stage classifi-
cation and outcome criteria as described by Martin et al.10
The institutional review board of the Vall d’Hebron Uni-
versity Hospital approved the study. The patient signed a
written informed consent for publication of the case report.
CASE
A 40-year-old woman from the Dominican Republic pre-
sented at the emergency room in August 2012 with an 8-month
history of gait disturbances and falls. The patient had been
living in Spain for the last 14 years and reported no travel
history in the last 5 years. Her previous medical status unveiled
a treated hyperthyroidism with a normal hormonal study in the
follow up, a major depression disorder, and urinary bladderappeared during the previous year and
nother center. She was under treatment
lifenacin succinate.
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A more accurate medical history revealed blurred vision
and muscle spasms. On physical examination on admission, the
patient had normal axillary temperature, blood pressure values,
and heart rate. Heart, lung, and abdominal examinations were
unremarkable. Skin examination showed a pruriginous papular
rash in the lower abdomen and scalp. Muscle strength was
slightly reduced in the lower limbs, where the deep tendon
reflexes were brisk and the reflex area expanded. Moreover, the
lower limbs were spastic and vibratory sensation was dimin-
ished. The Babinski sign was presented bilaterally. On eye
examination, uveitis was diagnosed.
In the blood test, the white cell count only showed a total
eosinophil count of 1000 cells/mm3 (10.2%). Biochemical
parameters remained within the normal range. Serological tests
for hepatitis B and C, human immunodeficiency virus, and
Strongyloides stercoralis were negative. Vitamin deficits and
autoantibody battery study were also within normal ranges.
Feces samples were negative for helminths. The tuberculin skin
test was performed twice with negative results.
A cranial and spinal magnetic resonance imaging demon-
strated small demyelinating focal lesions in the subcortical
white matter, mainly around the posterior portion of both oval
centers, conditioning Wallerian degeneration in the pyramidal
tracts bilaterally. The lesions showed no signs of activity.
The cerebrospinal fluid showed lymphocytic pleocytosis.
An oligoclonal band study was negative and microscopy did not
observe any atypical cells.
On electromyography examination, a severe involvement
of pyramidal and somatosensorial tracts for all 4 limbs was
diagnosed, suggesting demyelination. No signs of peripheral
neuropathy or motor neuron disease were detected.
Furthermore, a skin punch examination of the papular rash
of the lower abdomen demonstrated an atypical T phenotype
lymphoid infiltrate, suggesting an indolent lymphoma form;
however, T-cell receptor g, T-cell receptor b, and immunoglo-
bulin heavy chain reassortment studies were negative. T CD8
lymphocytes in the epidermis also suggested infective derma-
titis. Skin cultures were positive for methicillin-sensitive Sta-
phylococcus aureus.
A definitive HAM/TSP diagnosis was made with the
Sánchez-Montalvá et alinformation above, plus a positive serology for HTLV (enzyme
immunoassay Murex HTLV IþII; DiaSorin) and a positive
HTLV-1 proviral load in peripheral blood.12 The seropositivity
TABLE 1. Clinical and Laboratory Outcomes
Before Treatme






PVR urine volume (fluxometry), mL 247

Nocturia 4
Walking test (seconds to walk 10 m)y 33.66
b-2 Microglobulin, mg/L 2.2
IPEC¼ Instituto de Pesquisa Clı́nica Evandro Chagas disability score, MS
36¼SF-36 health survey scale, SPAST-88¼ spasticity scale-88 score.
Performed several weeks after treatment initiation.
yBoth tests performed with walking sticks.
2 | www.md-journal.comfor HTLV-1 was confirmed by line immunoassay (INNO-LIA
HTLV I/II Score; Innogenetics). Curiously, the line immuno-
assay also resulted positive for HTLV-2. The partner of the
patient also had antibodies against HTLV-1 and HTLV-2
confirmed by line immunoassay.
The HTLV-1 proviral load in the peripheral blood before
treatment was 1.767/10.000 peripheral blood mononucleated
cell. The proviral load from the cerebrospinal fluid was
not performed.
Clinical status was evaluated using the modified Ashworth
spasticity scale, spasticity scale-88 score (SPAST-88), SF-36
health survey scale (SF-36), multiple sclerosis walking scale,
Instituto de Pesquisa Clı́nica Evandro Chagas disability score
(IPEC), the Barthel scale, postvoid residual urine volume,
nocturia frequency (per night), and a walking test (time to walk
10 m). These tests were performed before treatment initiation
and after 62 weeks of treatment. Results are shown in Table 1.
Cyclosporine was started at 25 mg twice a day and titration
was done according to plasma cyclosporine levels. Target
plasma levels were 80 to 100 ng/mL, and were mainly achieved
with 50 mg twice daily.
Treatment was discontinued after 62 weeks. During this
time, the patient was closely monitored with blood tests and
physical examination. No side effects or evidence of TLL
were reported.
The clinical outcomes and the HTLV-1 proviral load in
peripheral blood are depicted in Tables 1 and 2, respectively.
DISCUSSION
Although HAM/TSP was described many years ago, lim-
ited efforts have been made to develop new and effective
therapies. Different biological approaches have been elaborated
to understand the pathogenesis of the disease, and therefore,
different treatment options have been tested with inconclusive
results, including interferon-a, interferon-g, antiretroviral
therapy, danazol, corticoids, valproic acid, monoclonal anti-
bodies anti-CD25, and others.9
Despite the fact that available scientific evidence does not
support any treatment, the interferon-a treatment strategy is the
Medicine  Volume 94, Number 1, January 2015most widely studied, and there appear to be benefits when
applied in the early or progressive stages of the disease. On the
contrary, steroids remain a useful resource for punctual use, but











WS-1¼multiple sclerosis walking scale, PVR¼ postvoid residual, SF-
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TABLE 2. HTLV-1 Proviral Load in Peripheral Blood
Proviral Load/ PBMCs
Before treatment 1.767/10.000
8 wk of treatment 947/10.000
31 wk of treatment 820/10.000
End of treatment 890/10.000
Medicine  Volume 94, Number 1, January 2015their activity seems temporary and treatment potency is lost
with continuous use.
Recently, a proof-of-concept study has supported a poten-
tial advantage when using cyclosporine, a steroid-sparing
therapy, in the early or progressive phase of the disease.10
Our baseline and end-of-treatment outcome criteria were com-
pared after 62 weeks of treatment, in contrast with the 48 weeks
of treatment and 72 weeks of follow-up in the proof-of-concept
study. Despite these differences, we think our experience
strengthens the outcomes obtained by Martin et al.10
The IPEC and walking tests were the main monitoring
criteria used, as they are stable over time and reproducible
because they are rarely modified by mood state or psychiatric
conditions. Other tests like SF-36 and SPAST-88 may be highly
dependent on mood state, so that a state of depression, usually
accompanying the disease, may alter the results. Our patient
showed a significant improvement in both the walking and
IPEC tests.
Cyclosporine levels were used to adjust the treatment dose.
Three out of the 8 cyclosporine levels were in the range between
80 and 100 ng/mL, 1 was above the upper limit, 2 were between
60 and 65 ng/mL, and 2 determinations were <50 ng/mL.
Notwithstanding, both determinations <50 ng/mL were the 2
first determinations (performed in the first month) when there
was titration of the dose. We can therefore say that cyclosporine
levels were within the normal range or above in 50% of the
determinations. Treatment was given under directly observed
treatment.
HTLV-1 proviral load was only assessed in peripheral
blood. Proviral load gradually declined during treatment, as
shown in Table 2. How cyclosporine attains this outcome is not
well understood.
Although the patient received immunosuppressive therapy
for over a year, no sign of hematological disease appeared.
However, a concern exists over whether a longer period of
treatment may increase the incidence of TLL. More data
HTLV¼ human T-lymphotropic virus, PBMC¼ peripheral blood
mononuclear cell.To summarize, we have reported the case of a patient
with an early HAM/TSP treated with cyclosporine, with a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.satisfactory clinical outcome after 62 weeks of treatment.
Cyclosporine seems to be effective in new-onset HAM/TSP
or in chronic HAM/TSP that develops a relapse. However, the
duration and safety profile of this steroid-sparing therapy
remain unknown and should be further investigated.
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